Literature DB >> 15613711

Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.

O John Semmes1, Ziding Feng, Bao-Ling Adam, Lionel L Banez, William L Bigbee, David Campos, Lisa H Cazares, Daniel W Chan, William E Grizzle, Elzbieta Izbicka, Jacob Kagan, Gunjan Malik, Dale McLerran, Judd W Moul, Alan Partin, Premkala Prasanna, Jason Rosenzweig, Lori J Sokoll, Shiv Srivastava, Sudhir Srivastava, Ian Thompson, Manda J Welsh, Nicole White, Marcy Winget, Yutaka Yasui, Zhen Zhang, Liu Zhu.   

Abstract

BACKGROUND: Protein expression profiling for differences indicative of early cancer has promise for improving diagnostics. This report describes the first stage of a National Cancer Institute/Early Detection Research Network-sponsored multiinstitutional evaluation and validation of this approach for detection of prostate cancer.
METHODS: Two sequential experimental phases were conducted to establish interlaboratory calibration and standardization of the surface-enhanced laser desorption (SELDI) instrumental and assay platform output. We first established whether the output from multiple calibrated Protein Biosystem II SELDI-ionization time-of-flight mass spectrometry (TOF-MS) instruments demonstrated acceptable interlaboratory reproducibility. This was determined by measuring mass accuracy, resolution, signal-to-noise ratio, and normalized intensity of three m/z "peaks" present in a standard pooled serum sample. We next evaluated the ability of the calibrated and standardized instrumentation to accurately differentiate between selected cases of prostate cancer and control by use of an algorithm developed from data derived from a single site 2 years earlier.
RESULTS: When the described standard operating procedures were established at all laboratory sites, the across-laboratory measurements revealed a CV for mass accuracy of 0.1%, signal-to-noise ratio of approximately 40%, and normalized intensity of 15-36% for the three pooled serum peaks. This was comparable to the intralaboratory measurements of the same peaks. The instrument systems were then challenged with sera from a selected group of 14 cases and 14 controls. The classification agreement between each site and the established decision algorithm were examined by use of both raw peak intensity boosting and ranked peak intensity boosting. All six sites achieved perfect blinded classification for all samples when boosted alignment of raw intensities was used. Four of six sites achieved perfect blinded classification with ranked intensities, with one site passing the criteria of 26 of 28 correct and one site failing with 19 of 28 correct.
CONCLUSIONS: These results demonstrate that "between-laboratory" reproducibility of SELDI-TOF-MS serum profiling approaches that of "within-laboratory" reproducibility as determined by measuring discrete m/z peaks over time and across laboratories.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15613711     DOI: 10.1373/clinchem.2004.038950

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  81 in total

1.  Selenium-responsive proteins in the sera of selenium-enriched yeast-supplemented healthy African American and Caucasian men.

Authors:  Raghu Sinha; Indu Sinha; Nicole Facompre; Stephen Russell; Richard I Somiari; John P Richie; Karam El-Bayoumy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-19       Impact factor: 4.254

2.  Depicting the spatial distribution of proteins in human tumor tissue combining SELDI and MALDI imaging and immunohistochemistry.

Authors:  Liane Wehder; Günther Ernst; Anna C Crecelius; Orlando Guntinas-Lichius; Christian Melle; Ulrich S Schubert; Ferdinand von Eggeling
Journal:  J Histochem Cytochem       Date:  2010-07-19       Impact factor: 2.479

Review 3.  Identifying molecular markers for the early detection of pancreatic neoplasia.

Authors:  Michael Goggins
Journal:  Semin Oncol       Date:  2007-08       Impact factor: 4.929

4.  Diverse range of small peptides associated with high-density lipoprotein.

Authors:  Glen L Hortin; Rong-Fong Shen; Brian M Martin; Alan T Remaley
Journal:  Biochem Biophys Res Commun       Date:  2005-12-27       Impact factor: 3.575

5.  Deconvolution filters to enhance resolution of dense time-of-flight survey spectra in the time-lag optimization range.

Authors:  Dariya I Malyarenko; William E Cooke; Eugene R Tracy; Michael W Trosset; O John Semmes; Maciek Sasinowski; Dennis M Manos
Journal:  Rapid Commun Mass Spectrom       Date:  2006       Impact factor: 2.419

6.  Resampling and deconvolution of linear time-of-flight records for enhanced protein profiling.

Authors:  Dariya I Malyarenko; William E Cooke; Eugene R Tracy; Richard R Drake; Susanna Shin; O John Semmes; Maciek Sasinowski; Dennis M Manos
Journal:  Rapid Commun Mass Spectrom       Date:  2006       Impact factor: 2.419

Review 7.  Enzymes and related proteins as cancer biomarkers: a proteomic approach.

Authors:  Shu-Ling Liang; Daniel W Chan
Journal:  Clin Chim Acta       Date:  2007-02-20       Impact factor: 3.786

8.  Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease.

Authors:  Manuel Aivado; Dimitrios Spentzos; Ulrich Germing; Gil Alterovitz; Xiao-Ying Meng; Franck Grall; Aristoteles A N Giagounidis; Giannoula Klement; Ulrich Steidl; Hasan H Otu; Akos Czibere; Wolf C Prall; Christof Iking-Konert; Michelle Shayne; Marco F Ramoni; Norbert Gattermann; Rainer Haas; Constantine S Mitsiades; Eric T Fung; Towia A Libermann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-12       Impact factor: 11.205

9.  Assessing the quality and reproducibility of a proteomic platform for clinical stroke biomarker discovery.

Authors:  Ediri Sideso; Michalis Papadakis; Cynthia Wright; Ashok Handa; Alastair Buchan; Benedikt Kessler; James Kennedy
Journal:  Transl Stroke Res       Date:  2010-08-14       Impact factor: 6.829

10.  Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.

Authors:  Dale McLerran; William E Grizzle; Ziding Feng; William L Bigbee; Lionel L Banez; Lisa H Cazares; Daniel W Chan; Jose Diaz; Elzbieta Izbicka; Jacob Kagan; David E Malehorn; Gunjan Malik; Denise Oelschlager; Alan Partin; Timothy Randolph; Nicole Rosenzweig; Shiv Srivastava; Sudhir Srivastava; Ian M Thompson; Mark Thornquist; Dean Troyer; Yutaka Yasui; Zhen Zhang; Liu Zhu; O John Semmes
Journal:  Clin Chem       Date:  2007-11-02       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.